How many insider trades does FilingIQ track for AURX?

FilingIQ tracks 73 Form 4 insider transactions for AURX (Nuo Therapeutics, Inc.), covering filings from May 10, 2017 onwards. 6 of those were filed in the last 90 days.

Are AURX insiders net buyers or net sellers?

Across the full Form 4 history for AURX, 11 transactions (15%) were open-market purchases and 10 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AURX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AURX in?

Nuo Therapeutics, Inc. (AURX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $77.25M.

AURX insider trading

OTC Markets OTCQB Healthcare

Nuo Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

15% / 14%

Market cap

$77.25M

About Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

Company website: www.nuot.com

AURX insider activity at a glance

FilingIQ has scored 73 insider transactions for AURX since May 10, 2017. The most recent filing in our index is dated Jun 5, 2026.

Across the full history, 11 open-market purchases and 10 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AURX insider trades is 62.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AURX trades on FilingIQ Raw filings on SEC EDGAR

Latest AURX Form 4 filings

JORDEN DAVID EMERSON CEO/CFO

S Nov 28, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,165

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

Top insiders trading AURX

JORDEN DAVID EMERSON

4 trades · score 75.0

Frequently asked

How many insider trades does FilingIQ track for AURX?: FilingIQ tracks 73 Form 4 insider transactions for AURX (Nuo Therapeutics, Inc.), covering filings from May 10, 2017 onwards. 6 of those were filed in the last 90 days.
Are AURX insiders net buyers or net sellers?: Across the full Form 4 history for AURX, 11 transactions (15%) were open-market purchases and 10 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AURX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AURX in?: Nuo Therapeutics, Inc. (AURX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $77.25M.

Methodology & sources

Every AURX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.